Why Cencora (COR) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research9/7/2026Positive
COR
Cencora Inc.NYSEHEALTHCAREMEDICAL DISTRIBUTION
Key Statistics
Market Cap
$63.15B
P/E Ratio
24.57
EPS
$13.47
Beta
0.57
52W High
$375.33
52W Low
$243.78
50-Day MA
$312.10
200-Day MA
$321.92
Dividend Yield
0.70%
Profit Margin
0.79%
Forward P/E
16.95
PEG Ratio
0.71
About Cencora Inc.
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
Fundamentals
| Revenue (TTM) | $332.77B |
| Gross Profit (TTM) | $13.18B |
| EBITDA | $5.55B |
| Operating Margin | 1.41% |
| Return on Equity | 96.90% |
| Return on Assets | 3.56% |
| Revenue/Share (TTM) | $1715.73 |
| Book Value | $15.99 |
| Price-to-Book | 21.09 |
| Price-to-Sales (TTM) | 0.19 |
| EV/Revenue | 0.22 |
| EV/EBITDA | 14.12 |
| Quarterly Earnings Growth (YoY) | 11.90% |
| Quarterly Revenue Growth (YoY) | 5.10% |
| Shares Outstanding | $190.83M |
| Float | $180.25M |
| % Insiders | 4.30% |
| % Institutions | 99.74% |
Historical Volatility
HV 10-Day
23.06%
HV 20-Day
31.18%
HV 30-Day
30.28%
HV 60-Day
27.53%
HV Rank
71.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($369.31 target)
4
Strong Buy8
Buy3
HoldLatest News
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
Zacks Investment Research9/4/2026Neutral
Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/4/2026Positive
Cencora Launches Cell and Gene Therapy Enablement for Health Systems
COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
Zacks Investment Research9/4/2026Neutral
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.
Zacks Investment Research9/3/2026Positive
Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance
Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. The fund was underweight in the communication services, health care and consumer discretionary sectors. Strong stock selection and an overweight in IT added to relative return. Weakness in energy partially offset the favorable results.
Seeking Alpha8/23/2026Positive
Why Cencora (COR) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research8/12/2026Positive
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research8/11/2026Positive
Here's Why Cencora (COR) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Investment Research8/10/2026Positive
Allspring Growth Fund Q2 2026 Performance Update
Allspring Growth Fund outperformed the Russell 3000 Growth Index during the quarter. Sandisk Corp. is riding the AI storage super-cycle. Shares of Cencora could not distribute in a 'risk-on' market.
Seeking Alpha8/6/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on COR and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/8/2026